These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 34910289)

  • 1. Psychedelic-Assisted Therapy for Substance Use Disorders and Potential Mechanisms of Action.
    Rieser NM; Herdener M; Preller KH
    Curr Top Behav Neurosci; 2022; 56():187-211. PubMed ID: 34910289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peak experiences and the afterglow phenomenon: when and how do therapeutic effects of hallucinogens depend on psychedelic experiences?
    Majić T; Schmidt TT; Gallinat J
    J Psychopharmacol; 2015 Mar; 29(3):241-53. PubMed ID: 25670401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cessation and reduction in alcohol consumption and misuse after psychedelic use.
    Garcia-Romeu A; Davis AK; Erowid F; Erowid E; Griffiths RR; Johnson MW
    J Psychopharmacol; 2019 Sep; 33(9):1088-1101. PubMed ID: 31084460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Psilocybin for treating substance use disorders?
    de Veen BT; Schellekens AF; Verheij MM; Homberg JR
    Expert Rev Neurother; 2017 Feb; 17(2):203-212. PubMed ID: 27684102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of recreational psychedelic substance use experiences classified by substance.
    Hase A; Erdmann M; Limbach V; Hasler G
    Psychopharmacology (Berl); 2022 Feb; 239(2):643-659. PubMed ID: 35031816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Awe: a putative mechanism underlying the effects of classic psychedelic-assisted psychotherapy.
    Hendricks PS
    Int Rev Psychiatry; 2018 Aug; 30(4):331-342. PubMed ID: 30260256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Classical Psychedelics as Therapeutics in Psychiatry - Current Clinical Evidence and Potential Therapeutic Mechanisms in Substance Use and Mood Disorders.
    Mertens LJ; Preller KH
    Pharmacopsychiatry; 2021 Jul; 54(4):176-190. PubMed ID: 33472250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Psychedelics as an emerging novel intervention in the treatment of substance use disorder: a review.
    DiVito AJ; Leger RF
    Mol Biol Rep; 2020 Dec; 47(12):9791-9799. PubMed ID: 33231817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Psychedelic-Assisted Group Therapy: A Systematic Review.
    Trope A; Anderson BT; Hooker AR; Glick G; Stauffer C; Woolley JD
    J Psychoactive Drugs; 2019; 51(2):174-188. PubMed ID: 30950777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Psychedelics: Where we are now, why we got here, what we must do.
    Belouin SJ; Henningfield JE
    Neuropharmacology; 2018 Nov; 142():7-19. PubMed ID: 29476779
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Psychedelic-assisted therapies: The past, and the need to move forward responsibly.
    Gardner J; Carter A; O'Brien K; Seear K
    Int J Drug Policy; 2019 Aug; 70():94-98. PubMed ID: 31136924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Associations of Naturalistic Classic Psychedelic Use, Mystical Experience, and Creative Problem Solving.
    Sweat NW; Bates LW; Hendricks PS
    J Psychoactive Drugs; 2016; 48(5):344-350. PubMed ID: 27719438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicting changes in substance use following psychedelic experiences: natural language processing of psychedelic session narratives.
    Cox DJ; Garcia-Romeu A; Johnson MW
    Am J Drug Alcohol Abuse; 2021 Jul; 47(4):444-454. PubMed ID: 34096403
    [No Abstract]   [Full Text] [Related]  

  • 14. Classic hallucinogens in the treatment of addictions.
    Bogenschutz MP; Johnson MW
    Prog Neuropsychopharmacol Biol Psychiatry; 2016 Jan; 64():250-8. PubMed ID: 25784600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treating Addiction: Perspectives from EEG and Imaging Studies on Psychedelics.
    Tófoli LF; de Araujo DB
    Int Rev Neurobiol; 2016; 129():157-85. PubMed ID: 27503452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Classic Psychedelics in Addiction Treatment: The Case for Psilocybin in Tobacco Smoking Cessation.
    Johnson MW
    Curr Top Behav Neurosci; 2022; 56():213-227. PubMed ID: 35704271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Posttraumatic Stress Disorder After a Psychedelic Experience, a Case Report.
    Rubin-Kahana DS; Hassan AN; Le Foll B
    J Addict Med; 2021 May-Jun 01; 15(3):248-251. PubMed ID: 32925231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Persisting Reductions in Cannabis, Opioid, and Stimulant Misuse After Naturalistic Psychedelic Use: An Online Survey.
    Garcia-Romeu A; Davis AK; Erowid E; Erowid F; Griffiths RR; Johnson MW
    Front Psychiatry; 2019; 10():955. PubMed ID: 32038317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Psychedelic Psychiatry: Preparing for Novel Treatments Involving Altered States of Consciousness.
    Holoyda B
    Psychiatr Serv; 2020 Dec; 71(12):1297-1299. PubMed ID: 33050796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A review of emerging therapeutic potential of psychedelic drugs in the treatment of psychiatric illnesses.
    Chi T; Gold JA
    J Neurol Sci; 2020 Apr; 411():116715. PubMed ID: 32044687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.